Effect of Colchicine on Neutrophil to Lymphocyte Ratio and Cardiac Function in Non-Diabetic Patients Post STEMI Using Speckle Tracking Imaging

Background: Acute myocardial ischemia is accompanied by myocardial necrosis and endogenous inflammation, resulting in myocardial injury, ventricular dilation, and dysfunction. Colchicine is a low cost, orally given and potent anti-inflammatory drug. Objective: To examine the effect of colchicine on inflammatory markers, such as neutrophil/lymphocyte ratio (NLR) and cardiac function in non-diabetic ST segment elevation myocardial infarction (STEMI) cases. Patients and Methods: Our research was done in the Cardiology Department, Aswan University Hospital through the period from December 2020 to December 2021 on 40 non-diabetic cases who presented with STEMI and underwent primary percutaneous intervention (PCI). Cases were then randomized into 2 groups: After reperfusion group (A) that consisted of 20 patients who were given anti-ischemic medication plus colchicine 0.5 mg once/day, while group (B) consisted of 20 participants who were given anti-ischemic treatment alone. Each participant had tests like NLR and CRP and an echocardiogram of their hearts performed at the beginning and at the end of the research. Results:Baseline NLR (P value > 0.05) and 1-month NLR (P value > 0.05) showed no statistically significant variance among groups. Also, did LVEF (p = 0.5), LVEDD (p = 0.63), LVESD (p = 0.29) and GLS (p = 0.91). Additionally, there was no statistical noteworthy change among groups in terms of LVEF, LVEDD and LVESD or global longitudinal strain (GLS) at follow-up. Conclusion: Adding colchicine to standard anti-ischemic treatment did not significantly enhance inflammatory indicators (NLR, CRP, and cardiac function) in non-diabetic individuals suffering from STEMI.